[{"id":"a688087c-68be-4853-9780-49620057e35d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04517851","created_at":"2021-01-18T21:38:49.784Z","updated_at":"2025-02-25T15:26:29.899Z","phase":"Phase 2","brief_title":"Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis","source_id_and_acronym":"NCT04517851","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2 • IL1R1 • SLAMF7","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • IL1R1 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Empliciti (elotuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/10/2021","start_date":" 02/10/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-10"},{"id":"8873703a-abd3-465c-96d4-165ce40e19a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04226950","created_at":"2021-01-18T20:33:33.025Z","updated_at":"2024-07-02T16:35:07.209Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","source_id_and_acronym":"NCT04226950","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 11/20/2024","study_completion_date":" 11/20/2024","last_update_posted":"2024-04-29"},{"id":"3256127a-0abe-4b2e-b192-b4bbda0ec654","acronym":"","url":"https://clinicaltrials.gov/study/NCT01594723","created_at":"2021-01-18T06:48:50.034Z","updated_at":"2024-07-02T16:35:13.492Z","phase":"Phase 2","brief_title":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT01594723","lead_sponsor":"Eli Lilly and Company","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gandotinib (LY 2784544)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/22/2012","start_date":" 05/22/2012","primary_txt":" Primary completion: 03/20/2015","primary_completion_date":" 03/20/2015","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-21"},{"id":"b2290004-6a3b-4c7e-a7e3-aba3da3fec16","acronym":"","url":"https://clinicaltrials.gov/study/NCT01423851","created_at":"2022-03-09T16:52:40.614Z","updated_at":"2024-07-02T16:36:15.706Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF","source_id_and_acronym":"NCT01423851","lead_sponsor":"NS Pharma, Inc.","biomarkers":" JAK2 • CD8 • IL6 • STAT3 • CD14","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CD8 • IL6 • STAT3 • CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 04/22/2020","primary_completion_date":" 04/22/2020","study_txt":" Completion: 04/22/2020","study_completion_date":" 04/22/2020","last_update_posted":"2022-03-09"},{"id":"72f0261f-678a-4aff-9ad3-ab9ceffa182c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02689336","created_at":"2021-01-18T13:07:01.533Z","updated_at":"2024-07-02T16:36:55.925Z","phase":"Phase 2","brief_title":"Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors","source_id_and_acronym":"NCT02689336","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • HER-2 • JAK2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • JAK2 V617F","tags":["EGFR • HER-2 • JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • temozolomide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/06/2016","start_date":" 08/06/2016","primary_txt":" Primary completion: 11/30/2019","primary_completion_date":" 11/30/2019","study_txt":" Completion: 05/31/2020","study_completion_date":" 05/31/2020","last_update_posted":"2019-09-09"},{"id":"fca6fe2f-706b-4bc8-9d90-aea678116342","acronym":"SAKK 33/14","url":"https://clinicaltrials.gov/study/NCT02311569","created_at":"2021-01-18T10:56:39.363Z","updated_at":"2024-07-02T16:36:59.538Z","phase":"Phase 2","brief_title":"Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation","source_id_and_acronym":"NCT02311569 - SAKK 33/14","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mirabegron"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2019-05-15"},{"id":"c2127c94-b5aa-4264-be7a-ee93fa6a03a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259856","created_at":"2021-01-18T05:04:56.061Z","updated_at":"2024-07-02T16:37:00.069Z","phase":"Phase 3","brief_title":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259856","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 06/30/2017","study_completion_date":" 06/30/2017","last_update_posted":"2019-04-30"},{"id":"0659227f-d0fb-4536-839e-0b6d4a52a25d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01134120","created_at":"2021-01-18T04:30:30.495Z","updated_at":"2024-07-02T16:37:11.464Z","phase":"Phase 1","brief_title":"A Study in Myeloproliferative Disorders","source_id_and_acronym":"NCT01134120","lead_sponsor":"Eli Lilly and Company","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F • JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gandotinib (LY 2784544)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 02/22/2018","study_completion_date":" 02/22/2018","last_update_posted":"2018-04-17"},{"id":"bb338bc0-84a5-416d-9940-f963dcb3cec6","acronym":"FAST","url":"https://clinicaltrials.gov/study/NCT02611973","created_at":"2021-01-18T12:41:23.906Z","updated_at":"2024-07-02T16:37:19.528Z","phase":"Phase 3","brief_title":"Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia","source_id_and_acronym":"NCT02611973 - FAST","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F • CALR mutation","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxyurea • aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 2250","initiation":"Initiation: 03/10/2016","start_date":" 03/10/2016","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2017-07-26"},{"id":"4debac25-5f39-463e-8915-abc74602ad24","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259817","created_at":"2021-01-18T05:04:55.274Z","updated_at":"2024-07-02T16:37:26.611Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259817","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 135","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-11"}]